↓ Skip to main content

Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy

Overview of attention for article published in Journal of Neural Transmission, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
3 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
33 Mendeley
Title
Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy
Published in
Journal of Neural Transmission, June 2018
DOI 10.1007/s00702-018-1893-1
Pubmed ID
Authors

Tommaso Schirinzi, Giulia Maria Sancesario, Giulia Di Lazzaro, Simona Scalise, Vito Luigi Colona, Paola Imbriani, Nicola Biagio Mercuri, Sergio Bernardini, Anthony E. Lang, Antonio Pisani

Abstract

Progressive Supranuclear Palsy (PSP) is a four-repeat tauopathy with high phenotypic and neuropathological variability, highlighting the urgent need for effective disease biomarkers. Quantitative analysis of cerebrospinal fluid (CSF) proteins reflecting pathological changes of CNS is currently used as biomarkers of multiple neurodegenerative disorders for both early differential diagnosis and prognostic clustering of patients. In this study, we thus assessed the clinical usefulness of a panel of CSF biomarker in PSP patients presenting with Richardson's Syndrome. CSF levels of 42-beta-amyloid, total-tau, phosphorylated-tau, and both 42-beta-amyloid/phosphorylated-tau and phosphorylated-tau/total-tau ratios were comparatively evaluated in 39 PSP patients, 31 patients with Parkinson's Disease (PD) and 58 gender-/age-matched healthy controls. Specific gold-standard clinical scores were obtained. Diagnostic accuracy and clinical correlates of each biomarker were measured with receiver operating curve analysis and Spearman's test/linear regression, respectively. In PSP, 42-beta-amyloid was lower than either controls or PD; total-tau and phosphorylated-tau were instead reduced compared to controls, but similar to PD. At the cut-off value of 623 pg/ml, 42-beta-amyloid significantly distinguished PSP from controls and PD. Likewise, phosphorylated-tau/total-tau ratio also supported differential diagnosis between PSP and PD (cut-off = 0.185). 42-beta-amyloid was inversely associated with PSP severity, as measured with PSP Rating Scale. Our study demonstrates that CSF 42-beta-amyloid is reduced in PSP patients, proportionally to clinical severity, thus suggesting a potential use as disease biomarker. Moreover, phosphorylated-tau/total-tau ratio resulted helpful in the early differential diagnosis between PSP and PD.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 21%
Student > Ph. D. Student 6 18%
Other 2 6%
Student > Doctoral Student 2 6%
Student > Master 2 6%
Other 4 12%
Unknown 10 30%
Readers by discipline Count As %
Neuroscience 9 27%
Medicine and Dentistry 6 18%
Biochemistry, Genetics and Molecular Biology 2 6%
Nursing and Health Professions 1 3%
Physics and Astronomy 1 3%
Other 3 9%
Unknown 11 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 July 2023.
All research outputs
#3,043,551
of 24,176,243 outputs
Outputs from Journal of Neural Transmission
#159
of 1,859 outputs
Outputs of similar age
#60,862
of 332,758 outputs
Outputs of similar age from Journal of Neural Transmission
#2
of 12 outputs
Altmetric has tracked 24,176,243 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,859 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,758 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.